GB0820397D0 - Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases - Google Patents

Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Info

Publication number
GB0820397D0
GB0820397D0 GBGB0820397.8A GB0820397A GB0820397D0 GB 0820397 D0 GB0820397 D0 GB 0820397D0 GB 0820397 A GB0820397 A GB 0820397A GB 0820397 D0 GB0820397 D0 GB 0820397D0
Authority
GB
United Kingdom
Prior art keywords
cells
constructs
diseases
treatment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0820397.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tigenix SA
Original Assignee
Cellerix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellerix SA filed Critical Cellerix SA
Priority to GBGB0820397.8A priority Critical patent/GB0820397D0/en
Publication of GB0820397D0 publication Critical patent/GB0820397D0/en
Priority to US13/128,145 priority patent/US9012220B2/en
Priority to KR1020117012368A priority patent/KR101666692B1/ko
Priority to EP09748336.6A priority patent/EP2361261B1/en
Priority to JP2011535119A priority patent/JP5745419B2/ja
Priority to AU2009312700A priority patent/AU2009312700B2/en
Priority to PCT/EP2009/064788 priority patent/WO2010052313A1/en
Priority to ES09748336T priority patent/ES2479540T3/es
Priority to CA2742698A priority patent/CA2742698C/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0820397.8A 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases Ceased GB0820397D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
US13/128,145 US9012220B2 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
KR1020117012368A KR101666692B1 (ko) 2008-11-07 2009-11-06 세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법
EP09748336.6A EP2361261B1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
JP2011535119A JP5745419B2 (ja) 2008-11-07 2009-11-06 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法
AU2009312700A AU2009312700B2 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
PCT/EP2009/064788 WO2010052313A1 (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
ES09748336T ES2479540T3 (es) 2008-11-07 2009-11-06 Células, construcciones de ácidos nucleicos, células que comprenden dichas construcciones y métodos de utilización de dichas células en el tratamiento de enfermedades
CA2742698A CA2742698C (en) 2008-11-07 2009-11-06 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0820397.8A GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Publications (1)

Publication Number Publication Date
GB0820397D0 true GB0820397D0 (en) 2008-12-17

Family

ID=40139550

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0820397.8A Ceased GB0820397D0 (en) 2008-11-07 2008-11-07 Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

Country Status (9)

Country Link
US (1) US9012220B2 (https=)
EP (1) EP2361261B1 (https=)
JP (1) JP5745419B2 (https=)
KR (1) KR101666692B1 (https=)
AU (1) AU2009312700B2 (https=)
CA (1) CA2742698C (https=)
ES (1) ES2479540T3 (https=)
GB (1) GB0820397D0 (https=)
WO (1) WO2010052313A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
ES2479565T1 (es) * 2011-03-11 2014-08-20 Tigenix, S.A.U. Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos
EP3985106A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population
EP3985105A1 (en) * 2020-10-16 2022-04-20 Uniwersytet Gdanski Conditioned regulatory t cell population tregs with enhanced therapeutic potential, method for obtaining of conditioned tregs and the medical use of the tregs population

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029310A2 (en) * 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
EP1252897A4 (en) 2000-01-21 2003-07-30 Hisamitsu Pharmaceutical Co MEDICINES FOR GENE THERAPY
EP1501918A4 (en) * 2002-04-12 2006-03-29 Med College Georgia Res Inst ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE
EP1369114A1 (en) 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents
ES2368152T3 (es) * 2005-07-01 2011-11-14 Txcell S.A. Obtención de células tr1 específicas de antígenos de los alimentos o de autoantígenos a partir de una población de leucocitos o pbmc.
EP3184630B1 (en) 2005-09-23 2019-07-17 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
CA2634072A1 (en) 2005-12-21 2007-06-28 Universite De Montreal Markers for memory t cells and uses thereof
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US20080155704A1 (en) * 2006-12-22 2008-06-26 King's College London Methods and Compositions for Determining in vivo Activity of BiP
WO2008100562A2 (en) 2007-02-14 2008-08-21 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
US8685728B2 (en) * 2008-01-31 2014-04-01 Rutgers The State University Of New Jersey Kit containing stem cells and cytokines for use in attenuating immune responses
WO2009155477A1 (en) * 2008-06-19 2009-12-23 The Trustees Of The University Of Pennsylvania Inducible regulatory t-cell generation for hematopoietic transplants

Also Published As

Publication number Publication date
CA2742698C (en) 2017-04-18
WO2010052313A1 (en) 2010-05-14
EP2361261A1 (en) 2011-08-31
KR101666692B1 (ko) 2016-10-17
ES2479540T1 (es) 2014-08-20
EP2361261B1 (en) 2016-01-27
ES2479540T3 (es) 2016-05-20
US9012220B2 (en) 2015-04-21
JP2012507997A (ja) 2012-04-05
AU2009312700A1 (en) 2010-05-14
JP5745419B2 (ja) 2015-07-08
US20120064031A1 (en) 2012-03-15
KR20110123721A (ko) 2011-11-15
CA2742698A1 (en) 2010-05-14
AU2009312700B2 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
GB2470672B (en) Methods of RNA amplification in the presence of DNA
IL201420A0 (en) Nucleic acid enzymes and complexes and methods for their use
IL208518A0 (en) Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
ZA200904684B (en) Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
WO2010083170A3 (en) Cell stimulation using quantum dots
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
SI2494039T1 (sl) Postopek reprogramiranja celic in njihova uporaba
IL207449A0 (en) Genetically modified cyanobacteria, methods of producing the same and methods of producing ethanol utilizing the same
IL213450A0 (en) Modified rsv f proteins and methods of their use
WO2012046084A3 (en) Short rna molecules
PL2412718T3 (pl) Primer w kształcie pętli stosowany w amplifikacji kwasów nukleinowych i jego zastosowanie
EP2337867A4 (en) DETECTION OF NPM1 NUCLEIC ACID IN ACELLULAR BODILY FLUIDS
ZA200700456B (en) Nucleic acid molecules and their use in plant male sterility
IL204668A0 (en) Use of sulfonyl - substituted 2 - sulfonylaminobenzoic acid n - phenylamides in the treatment of pain
GB0820397D0 (en) Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
PL2084272T3 (pl) Klonowanie, ekspresja oraz zastosowanie kwaśnych lizofosfolipaz
SG10201506725QA (en) Sdf-1 binding nucleic acids and the use thereof in cancer treatment
EP2405001A4 (en) NUCLEIC ACID COMPLEX AND NUCLEIC ACID DELIVERING COMPOSITION
IL209604A (en) Isolated cell populations, methods for their creation and use in the treatment of central nervous system diseases
WO2013079924A3 (en) Modified exonuclease
WO2011009082A3 (en) Compositions comprising human rhbdf1-modulating nucleic acids and methods of use
HUP0700594A2 (en) Composition and process for the protection and increasing the number of stem cells in the blood circulation and for enhancing p53 gene expression
EP2367805A4 (en) NUCLEIC ACIDS BASED ON MODIFIED ACTINOMYCINES AND METHOD FOR THEIR USE
EP2171069A4 (en) INTRODUCTION OF NUCLEIC ACIDS IN HUMAN STEM CELL GENOMES USING IN VITRO ASSEMBLED MU TRANSPOSITION COMPLEXES
IL208395A0 (en) Methods of expressing a ploypeptide in the brain and nucleic acid constructs capable of same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)